In conclusion, we show that our heterologous prime-boost vaccination inducing cross-presenting cDC1s and CD4+ T cells convey a potent anti-tumor CD8+ T-cell response in both immune excluded and infiltrated mouse cancer models. Here, CD8A is linked to neoplasm.